top of page
Logo-em-branco.png

Can bupropion treat COVID-19-induced brain fog? A case series

  • Foto do escritor: Dr. Galiano Brazuna Moura
    Dr. Galiano Brazuna Moura
  • 2 de jul. de 2023
  • 1 min de leitura

Atualizado: há 3 dias


A modern and conceptual digital illustration of a human silhouette in profile in deep blue and purple tones. The posterior half of the brain is enveloped in a dark and chaotic fog of tangled lines and virus symbols, labeled 'COVID-19 FOG'. A transition of brilliant golden light and clear synaptic connections advances to the frontal half of the brain, where the text 'BUPROPION' and integrated molecular models symbolize the restoration of cognitive clarity. In the bottom right corner, there is the logo of Dr. Galiano Brazuna Moura.

COVID-19-induced neurocognitive complications that include brain fog have affected a large portion of individuals who survived COVID-19. These symptoms can include inattention, mental fatigue, forgetfulness, amotivation, and distractibility. This can cause significant anxiety and depression, which may worsen disease progression. To date, there are no known specific treatments that target COVID-19-related brain fog. Here, two patients are presented that develop symptoms of brain fog that persisted after they recovered from an acute COVID-19 infection. Both had memory impairment, mental exhaustion, and inattention with associated depressed mood. They were given bupropion extended release and though varied with dosing and time to resolution, they recovered dramatically. The dopamine and norepinephrine reuptake inhibitor is known to have effects on the brain that may treat symptoms of brain fog including blocking hippocampal cell loss, increased neural activity in the cingulate cortex, and decreasing proinflammatory cytokines. Bupropion may be a possible option for those suffering from this growing and debilitating post-COVID-19 complication.




Comentários


bottom of page